Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 44 of 151

  1. D7080C00001

    AstraZeneca AB

    Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  2. D7230C00001

    AstraZeneca AB

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  3. D7260C00001

    AstraZeneca AB

    Participants living with Obesity or Overweight with at least 1 comorbidity

    phase 2 small molecule active

    1 trial

  4. D7261C00001

    AstraZeneca AB

    Type 2 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  5. D7405C00001 (SYRUS)

    AstraZeneca AB

    B-Cell Acute Lymphoblastic Leukaemia

    phase 2 small molecule active

    1 trial

  6. D7407C00001

    AstraZeneca AB

    Mantle Cell Lymphoma, Large B-Cell Lymphoma, Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  7. D7552C00001

    AstraZeneca AB

    Moderate-to-Severe Uncontrolled Asthma

    phase 2 small molecule active

    1 trial

  8. D7830C00004

    AstraZeneca AB

    Non-cirrhotic non-alcoholic steatohepatitis with fibrosis

    phase 2 small molecule active

    1 trial

  9. D7860C00006

    AstraZeneca AB

    Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

    phase 2 small molecule active

    1 trial

  10. D7986C00001

    AstraZeneca AB

    Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  11. D798KC00001

    AstraZeneca AB

    Solid Tumors, SQ, NSQ NSCLC

    phase 2 small molecule active

    1 trial

  12. D798MC00002

    AstraZeneca AB

    Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).

    phase 2 small molecule active

    1 trial

  13. D8210C00003

    AstraZeneca AB

    Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

    phase 2 small molecule active

    1 trial

  14. D8210C00005

    AstraZeneca AB

    Asthma

    phase 2 small molecule active

    1 trial

  15. D8220C00036

    AstraZeneca AB

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

    phase 2 small molecule active

    1 trial

  16. D822GC00001

    AstraZeneca AB

    Treatment Naïve Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  17. D8410C00001

    AstraZeneca AB

    Module 1: advanced/relapsed ovarian, breast, pancreatic or prostate cancer where patients loss of function or predicted loss of function mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, Module 4: advanced,unresectable and HER2+ metastatic solid tumours; NSCLC, HER2 activating mutation, Module 5: advanced,unresectable or metastatic solid tumours in breast, endometrial, ovarian and prostate cancer, Module 3: advanced/relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancer and expressing BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm, IDH-mutant recurrent glioma, breast cancer (without BM), Module 2: IDH-mutant glioma

    phase 2 small molecule active

    1 trial

  18. D8460C00004

    AstraZeneca AB

    Investigating obesity or overweight condition correlated to many co-morbidities

    phase 2 small molecule active

    1 trial

  19. D8530C00002

    AstraZeneca AB

    Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  20. D9077C00001

    AstraZeneca AB

    Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. D9090C00008

    AstraZeneca AB

    Chronic Heart Failure

    phase 2 small molecule active

    1 trial

  22. D9102C00001

    AstraZeneca AB

    Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusions

    phase 2 small molecule active

    1 trial

  23. D9106C00002

    AstraZeneca AB

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  24. D9181C00002

    AstraZeneca AB

    Asthma

    phase 2 small molecule active

    1 trial

  25. D933LC00001

    AstraZeneca AB

    First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.

    phase 2 small molecule active

    1 trial

  26. D9520C00001

    AstraZeneca AB

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  27. D9571C00001

    AstraZeneca AB

    Relapsed/Refractory Classical Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  28. D967LC00001

    AstraZeneca AB

    Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer

    phase 2 small molecule active

    1 trial

  29. D9690C00006

    AstraZeneca AB

    Crohn’s Disease and an Ileostomy

    phase 2 small molecule active

    1 trial

  30. D9720C00001

    AstraZeneca AB

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  31. D9720C00003

    AstraZeneca AB

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  32. D9804C00001

    AstraZeneca AB

    Locally Advanced Resectable Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  33. DA-302168S

    Chendu DIAO Pharmaceutical Group CO., LTD.

    Overweight and Obesity

    phase 2 small molecule active

    1 trial

  34. DA-4001C

    Dong Wang

    Androgenetic Alopecia

    phase 2 small molecule completed

    1 trial

  35. DA-EPOCH

    The First People's Hospital of Lianyungang

    NHL With Hemophagocytic Lymphohistiocytosis

    phase 2 small molecule active

    1 trial

  36. DAAOI-P

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson's Disease With Dementia

    phase 2 small molecule completed

    1 trial

  37. DABRAFENIB , TRAMETINIB

    Disc Medicine

    ANAPLASTIC THYROID CANCER

    phase 2 small molecule active

    1 trial

  38. DAOIB

    Hospital Authority, Hong Kong

    Long COVID

    phase 2 small molecule active

    1 trial

  39. DARATUMUMAB for Relapsed or Refractory Plasmablastic lymphoma

    Fondazione Telethon ETS

    Relapsed or Refractory Plasmablastic lymphoma

    phase 2 small molecule active

    1 trial

  40. DAROTAXEL

    Disc Medicine

    metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  41. DASATINIB, Placebo

    The George Institute

    Asymptomatic patients with recent HIV-1 infection

    phase 2 small molecule active

    1 trial

  42. DB-OTO

    Regeneron UK Limited

    Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

    phase 2 gene therapy active

    1 trial

  43. DB-OTO

    Lacuna Pharma Pty Ltd

    Congenital Hearing Loss Secondary to Biallelic Pathogenic Variants of the Otoferlin Gene (OTOF)

    phase 2 small molecule active

    1 trial

  44. DC-CIK Immunotherapy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 mab active

    1 trial

  45. DC-VACCINE_IRSTIRCCS for Stage IV colorectal cancer

    Istituto Gentili S.r.l.

    Stage IV colorectal cancer

    phase 2 small molecule active

    1 trial

  46. DC1 Vaccine

    United Therapeutics Europe Ltd

    Breast Cancer Female

    phase 2 mab active

    1 trial

  47. DCC-3014-01-001

    Lacuna Pharma Pty Ltd

    Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

    phase 2 small molecule active

    1 trial

  48. DCC-3084, DCC-3084

    Lacuna Pharma Pty Ltd

    Solid tumors driven by the MAPK Pathway

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.